[Evaluation of anti-atheromatous properties of calcium channel inhibitors].
Calcium is involved in several biochemical atherogenesis processes and its activity is antagonised in cell and animal experimental models by all classes of slow channel calcium inhibitors. However, the doses required in animals to slow the development of atherosclerotic lesions are above therapeutically acceptable doses in man. The clinical relevance of their anti-atherosclerotic activity in the few clinical studies undertaken is difficult to assess because of the variable criteria of judgment used.
Drici
M D
MD
Laboratoire de pharamacologie expérimentale et clinique, Faculté de médecine, Nice.
Coccoz
F
F
Morand
P
P
Lapalus
P
P
D000818:Animals; D001161:Arteriosclerosis / Q000188:drug therapy / Q000503:physiopathology* / Q000517:prevention & control; D002121:Calcium Channel Blockers / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D006937:Hypercholesterolemia / Q000150:complications; D006973:Hypertension / Q000150:complications / Q000188:drug therapy; D009131:Muscle, Smooth, Vascular / Q000187:drug effects*; D011817:Rabbits; D051381:Rats; D012107:Research Design
D002121:Calcium Channel Blockers
Evaluation des propriétés antiathéromateuses des inhibiteurs calciques.